Literature DB >> 12018736

Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention.

A H Miners1, A Holmes, L Sherr, C Jenkinson, K D MacDermot.   

Abstract

Anderson Fabry Disease (AFD) is an extremely painful and debilitating multi-system X-linked disorder due to alpha-galactosidase enzyme deficiency. To date, no baseline data on health-related quality-of-life (HR-QoL) have been reported in males affected with this condition. In this study, 38 males with AFD completed Medical Outcomes Study Short Form, EuroQoL questionnaires and an AFD-specific questionnaire prior to the start of a trial involving replacement therapy with alpha-galactosidase. Results from these questionnaires were compared to the results from a similar HR-QoL study in males with severe haemophilia (factor VIII/IX deficiency) that used the same questionnaires and to the results of two large normative studies. The results on both questionnaires showed that in most instances males with AFD recorded significantly lower HR-QoL compared with males in the general population and individuals with severe haemophilia after adjusting for differences in age. These findings suggest therefore, that the scope for improvement in HR-QoL as a result of treatment with an appropriate agent is extremely large.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12018736     DOI: 10.1023/a:1015009210639

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  10 in total

1.  Assessing health-related quality-of-life in individuals with haemophilia.

Authors:  A H Miners; C A Sabin; K H Tolley; C Jenkinson; P Kind; C A Lee
Journal:  Haemophilia       Date:  1999-11       Impact factor: 4.287

2.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

3.  The SF-36 physical and mental health summary measures: an example of how to interpret scores.

Authors:  C Jenkinson
Journal:  J Health Serv Res Policy       Date:  1998-04

4.  Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

Authors:  I M Nilsson; E Berntorp; T Löfqvist; H Pettersson
Journal:  J Intern Med       Date:  1992-07       Impact factor: 8.989

5.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

6.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

7.  Variations in population health status: results from a United Kingdom national questionnaire survey.

Authors:  P Kind; P Dolan; C Gudex; A Williams
Journal:  BMJ       Date:  1998-03-07

8.  Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.

Authors:  C Jenkinson; A Coulter; L Wright
Journal:  BMJ       Date:  1993-05-29

9.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

10.  Prevalence of lysosomal storage disorders.

Authors:  P J Meikle; J J Hopwood; A E Clague; W F Carey
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

  10 in total
  23 in total

Review 1.  Quality of life in rare genetic conditions: a systematic review of the literature.

Authors:  Julie S Cohen; Barbara B Biesecker
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

2.  Natural history of Fabry disease in females in the Fabry Outcome Survey.

Authors:  P B Deegan; A F Baehner; M-A Barba Romero; D A Hughes; C Kampmann; M Beck
Journal:  J Med Genet       Date:  2005-10-14       Impact factor: 6.318

3.  Fabry disease: multidisciplinary evaluation after 10 years of treatment with agalsidase Beta.

Authors:  Politei Juan; Amartino Hernan; Schenone Andrea Beatriz; Cabrera Gustavo; Michref Antonio; Tanus Eduardo; Dominguez Raul; Larralde Margarita; Blanco Mariana; Gaggioli Daniela; Szlago Marina
Journal:  JIMD Rep       Date:  2014-05-22

4.  Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience.

Authors:  Joanna Ghali; Kathy Nicholls; Charles Denaro; David Sillence; Ian Chapman; Jack Goldblatt; Mark Thomas; Janice Fletcher
Journal:  JIMD Rep       Date:  2011-09-15

5.  Cognitive and psychological functioning in Fabry disease.

Authors:  Linda Sigmundsdottir; Michel C Tchan; Alex A Knopman; Graham C Menzies; Jennifer Batchelor; David O Sillence
Journal:  Arch Clin Neuropsychol       Date:  2014-11       Impact factor: 2.813

6.  Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Authors:  B Hoffmann; A Garcia de Lorenzo; A Mehta; M Beck; U Widmer; R Ricci
Journal:  J Med Genet       Date:  2005-03       Impact factor: 6.318

Review 7.  Enzyme replacement therapy of Fabry disease.

Authors:  Joe T R Clarke; R Mark Iwanochko
Journal:  Mol Neurobiol       Date:  2005-08       Impact factor: 5.590

8.  Social-adaptive and psychological functioning of patients affected by Fabry disease.

Authors:  Dawn Alyssia Laney; Daniel J Gruskin; Paul M Fernhoff; Joseph F Cubells; Opal Y Ousley; Heather Hipp; Ami J Mehta
Journal:  J Inherit Metab Dis       Date:  2010-01-20       Impact factor: 4.982

Review 9.  Fabry disease-often seen, rarely diagnosed.

Authors:  Björn Hoffmann; Ertan Mayatepek
Journal:  Dtsch Arztebl Int       Date:  2009-06-26       Impact factor: 5.594

10.  Fabry disease in children and the effects of enzyme replacement treatment.

Authors:  Guillem Pintos-Morell; Michael Beck
Journal:  Eur J Pediatr       Date:  2009-02-26       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.